Format

Send to

Choose Destination
J Antimicrob Chemother. 2004 Feb;53(2):325-8. Epub 2004 Jan 16.

Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.

Author information

1
Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, York Road, Leeds LS14 6UH, UK.

Abstract

OBJECTIVES:

Linezolid is a new oxazolidinone antibiotic with efficacy against a broad range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In this study, we have determined the serum and sputum linezolid concentrations in adults with cystic fibrosis (CF) following oral drug administration.

METHODS:

Eleven adult patients with CF were recruited. Subjects received 600 mg of linezolid orally every 12 h for a total of six doses. Serum and sputum levels were measured just before and at 2 h after the final dose of linezolid. A further serum level was measured at 4 h.

RESULTS:

Ten adult patients completed the study. Mean (s.d.) serum linezolid concentrations were 2.3 mg/L (1.5) at 12 h following the fifth dose. At 2 and 4 h following the sixth dose, concentrations were 13.5 (4.3) and 8.1 (3.3). Mean (s.d.) linezolid sputum concentrations were 3.6 (2.1) and 17.4 (7.2) mg/L at 0 and 2 h following drug administration.

CONCLUSIONS:

The oral administration of linezolid results in good sputum penetration in patients with CF. Mean levels exceed the required MIC for the treatment of MRSA for >80% of the dosing period for serum and the majority of the dosing period for sputum.

PMID:
14729733
DOI:
10.1093/jac/dkh072
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center